The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).
Michael S. Gordon
Research Funding - Genentech
David E. Gerber
Research Funding - Genetic Technologies
Jeffrey R. Infante
No relevant relationships to disclose
Jian Xu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
David S. Shames
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Younjeong Choi
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Robert S. Kahn
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Kedan Lin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Katie Wood
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel J. Maslyar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Howard A. Burris
No relevant relationships to disclose